We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · June 16, 2021

Low Serum Neurofilament Light Chain Values Identify Optimal Responders to Dimethyl Fumarate in Multiple Sclerosis Treatment

Scientific reports

 

Additional Info

Disclosure statements are available on the authors' profiles:

Scientific reports
Low Serum Neurofilament Light Chain Values Identify Optimal Responders to Dimethyl Fumarate in Multiple Sclerosis Treatment
Sci Rep 2021 Apr 29;[EPub Ahead of Print], PE Walo-Delgado, S Sainz de la Maza, N Villarrubia, E Monreal, S Medina, M Espiño, JI Fernández-Velasco, E Rodríguez-Martín, E Roldán, D Lourido, A Muriel, J Masjuan-Vallejo, L Costa-Frossard, LM Villar

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading